expand_less


With an estimated 23% of the UK population classed as obese, the country has the second highest rate of obesity in Europe. However, obesity is just the tip of the iceberg as treatment can be dispensed to those who classed as overweight with a BMI of over 26 for some products, and over 26 with co-morbidities for others (please refer to product SPCs).

biopanda biopanda biopanda

Orlistat 120mg Information

About the PGD(s)

Treatments available:
• Orlistat (Xenical®) 120mg Hard Capsules.
• Mysimba® 8 mg/90 mg (8 mg naltrexone hydrochloride/90mg bupropion hydrochloride) prolonged release tablets.
• Saxenda® 6 mg/ml (liraglutide) solution for injection in pre-filled pen.

Price: £39.00

  • The Orlistat 120mg includes the following resources

    Choice of one to three PGDs for the supply of three approved weight loss products: Orlistat (Xenical) 120mg Hard Capsules; Mysimba 8 mg/90 mg (8 mg naltrexone hydrochloride/90mg bupropion hydrochloride) prolonged release tablets; Saxenda 6 mg/ml (liraglutide) solution for injection in pre-filled pen.

    Most inclusive Weight Loss PGD service available. Includes: Online resources, online assessment, Standard Operating Procedures, Risk Assessment Forms. For Saxenda, injection technique training is required (please contact PharmaDoctor for details). Easy online PGD access and authorisation - no paper copy required.


All our PGD service packages come with free access to our 9-5 Monday to Friday clinical support and medical information line.

 


Why this PGD service

The provision of NHS weight loss treatments is restrictive. A private service offers access for many patients who have failed on weight loss treatments previously or want access to licensed medicines not available on the NHS. PharmaDoctor offer orlistat, Mysimba® and Saxenda® as options. With Mysimba® not being available on the NHS, and with the NHS offering limited access to Saxenda® at the time of writing. Those interested in delivering a service including Mysimba® and Saxenda® require training by PharmaDoctor's specialist trainer (please contact the switchboard for information).


Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to the relevant pharmaceutical company.